What non‑stimulant medications (e.g., viloxazine [Qelbree], atomoxetine [Strattera], bupropion) can be tried for a patient with ADHD who reports that Adderall was the only medication that helped?

Non-Stimulant ADHD Treatment Options When Adderall Was Previously Effective

For a patient who reports Adderall was the only medication that helped, atomoxetine (Strattera) should be tried first among non-stimulants, followed by viloxazine (Qelbree) if atomoxetine fails, with bupropion reserved as a third-line option only when FDA-approved non-stimulants are ineffective or not tolerated.

Evidence-Based Treatment Algorithm

First-Line Non-Stimulant: Atomoxetine (Strattera)

Atomoxetine is the most established non-stimulant option with the strongest evidence base. Current guidelines consistently recommend atomoxetine as the primary non-stimulant alternative when stimulants cannot be used 1.

• Effect size: Approximately 0.7 compared to placebo (versus 1.0 for stimulants) 2
• Onset of action: 6-12 weeks for full therapeutic effect 1
• Dosing: Start at lower doses and titrate based on response; can be given once daily or split into morning/evening doses to reduce side effects 1
• Advantages: "Around-the-clock" coverage, non-controlled substance, fewer appetite/growth effects than stimulants 1
• Key consideration: FDA black box warning for suicidal ideation in children/adolescents 3

Second-Line Non-Stimulant: Viloxazine ER (Qelbree)

If atomoxetine fails or is not tolerated, viloxazine represents a newer evidence-based option 1, 4, 5.

• Mechanism: Serotonin-norepinephrine modulator with faster onset than atomoxetine (1-2 weeks vs 4 weeks) 4
• Evidence: Multiple Phase III trials demonstrate significant efficacy in children, adolescents, and adults 4, 5, 6
• Effect size: Modest but statistically significant (Hedges' g = -0.33 in adolescents) 6
• Dosing: Start 200 mg once daily, titrate weekly by 200 mg increments up to 600 mg/day maximum 7
• Side effects: Somnolence, fatigue, irritability, decreased appetite, headache 4
• Important: Also carries black box warning for suicidal ideation 4

Alpha-2 Agonists: Guanfacine and Clonidine

These medications have specific clinical niches but smaller effect sizes (approximately 0.7) 2, 1.

Consider guanfacine or clonidine when:

• Comorbid tic disorder or Tourette's syndrome exists 1
• Sleep disturbances are prominent 1
• Substance use disorder is present (stimulants contraindicated) 1
• As adjunctive therapy to stimulants (FDA-approved indication in US) 1

Key limitations:

• Onset: 2-4 weeks 1
• Common side effects: Somnolence, fatigue, hypotension, bradycardia 1
• Critical warning: Must taper when discontinuing to avoid rebound hypertension 8
• Evening dosing preferred due to sedation 1

Bupropion: Third-Line Off-Label Option

Bupropion should only be considered when FDA-approved non-stimulants have failed 9, 10.

• Evidence level: Limited compared to atomoxetine and viloxazine; not FDA-approved for ADHD
• Potential advantage: May be useful if comorbid depression exists 7
• Important caveat: Less efficacious than stimulants for ADHD core symptoms 7
• Clinical context: Guidelines do not recommend bupropion as a primary non-stimulant option 9

Critical Clinical Considerations

Setting Realistic Expectations

The patient must understand that no non-stimulant will match Adderall's efficacy. All non-stimulants have smaller effect sizes than stimulants 1. This is the most important counseling point—if Adderall was "the only medication that helped," non-stimulants may provide only partial symptom control.

Delayed Onset Requires Patience

Unlike stimulants with immediate effects, non-stimulants require weeks to months for full benefit:

• Atomoxetine: 6-12 weeks 1
• Viloxazine: 1-2 weeks 4
• Guanfacine/clonidine: 2-4 weeks 1

Premature discontinuation due to perceived inefficacy is a common pitfall.

Monitoring Requirements

For atomoxetine and viloxazine:

• Suicidality monitoring: Especially critical in first weeks of treatment and during dose changes 3
• Cardiovascular parameters: Blood pressure and heart rate 8
• Liver function: Atomoxetine can rarely cause hepatotoxicity 8, 3
• Growth parameters in children 8

For alpha-2 agonists:

• Blood pressure and heart rate (risk of hypotension/bradycardia) 8
• Cardiac history screening before initiation 8

Combination Strategies

If monotherapy with non-stimulants provides insufficient benefit, consider:

• Adding guanfacine or clonidine to atomoxetine (FDA-approved as adjunctive therapy in US) 1, 8
• Reassessing whether stimulant rechallenge is possible with different formulation or adjunctive strategies

Why This Hierarchy?

Atomoxetine first because it has the most extensive evidence base, longest track record, and is consistently recommended in guidelines as the primary non-stimulant 1. Viloxazine second because it represents a newer, well-studied alternative with potentially faster onset 4, 5. Alpha-2 agonists are positioned based on comorbidities and specific clinical scenarios rather than as general first-line alternatives 1. Bupropion last because it lacks FDA approval for ADHD and has weaker evidence compared to approved non-stimulants 9, 10.